BI-1831169
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BI-1831169, covering 2026-03-31 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) [Phase 1]